Novo Nordisk A/S

Novo Nordisk's CagriSema obesity shot showed 20.4% weight loss over 68 weeks, falling short of the 25% target. The results align with Eli Lilly's Zepbound, with Lilly's retatrutide showing up to 24% weight loss. Novo's shares dropped 27%, erasing $120 billion in market value, while Lilly's shares rose 10%. Novo plans to start a new trial in H1 2024 to optimize doses and expects regulatory approval by year-end 2024. The study suggests side effects may have limited patient adherence, with 22.7% weight loss in patients who stayed on treatment.

Catalent, Inc. and Novo Holdings A/S have fulfilled all regulatory closing conditions for their pending transaction, expected to close in the coming days. Catalent's CEO, Alessandro Maselli, expressed excitement for the company's future under Novo Holdings' ownership, emphasizing innovation and enhanced offerings. Jonathan Levy, Senior Partner at Novo Holdings, highlighted the benefits of the transaction for driving healthcare innovation and improving patient outcomes.

Eli Lilly's Mounjaro won't be reclassified as a sleep apnea treatment in Europe; its use for weight loss remains unchanged. The European Medicines Agency will include sleep apnea data in Mounjaro's product information. Lilly and Novo Nordisk compete for dominance in the obesity drug market, estimated to reach $130 billion by 2030. Mounjaro, branded as Zepbound in the US and Mounjaro in Europe, is also under FDA review for sleep apnea.

The Clinical Trials Market is projected to grow from US$483B in 2023 to US$886.5B by 2032, driven by personalized medicine, tech advancements, and chronic disease prevalence. North America leads, while Asia-Pacific grows rapidly. Key trends include AI, decentralized trials, and regulatory support for inclusivity and efficiency.

The oral proteins and peptides market is projected to grow to $2.86 billion by 2028 at a CAGR of 22.4%, driven by factors like rising chronic diseases, biotechnology investments, and non-invasive treatments. Key advancements include novel oral peptides, AI in drug discovery, and oral insulin formulations.

Sandoz Group AG plans to launch a generic Ozempic in Canada by 2026, betting on sustained demand for current GLP-1 weight-loss drugs despite new contenders. The company aims to produce a reliable generic version of semaglutide, the active ingredient in Ozempic, targeting Canada's large obesity market. Sandoz CEO Richard Saynor believes generics could significantly expand patient access if prices drop.

The biotechnology market, valued at USD 1.38 Trillion in 2023, is projected to reach USD 3.90 Trillion by 2031, driven by technological advancements, investment, and demand for sustainable solutions. Segments include type, product, technology, application, and region. Key trends are personalized medicine, CRISPR, sustainability, and telemedicine. Opportunities include increased funding, emerging markets, collaborations, and regulatory advancements. Major players include AstraZeneca, Gilead Sciences, Biogen, and Merck.

The eCOA, eSource, and clinical trials market is projected to grow from $44.85 billion in 2023 to $67.33 billion in 2028 at a CAGR of 8.3%, driven by technological advancements, increased demand for clinical trials, and adoption of patient-centric approaches.

DelveInsight's 'Hemophilia B Pipeline Insight 2024' report details 20+ pipeline drugs from 15+ companies, focusing on mechanism of action, route of administration, and molecule types. Key companies include Belief Biomed, TiumBio, and Pfizer, with therapies in various clinical stages. Notable recent developments include Novo Nordisk and ApcinteX trials in May 2024.

Global Human Growth Hormones Market to reach USD 10 billion by 2030, driven by increasing prevalence of growth hormone deficiency, product approvals, and adoption of recombinant HGH. North America dominates the market, with key players including Novo Nordisk, Pfizer, and Eli Lilly. Market growth is fueled by advancements in biotechnology and rising demand for targeted therapies, despite challenges like stringent regulations and high treatment costs.